January 01, 2026 05:38 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
No third party involved: India govt sources refute China’s Operation Sindoor ceasefire claim | Amit Shah blasts TMC over border fencing; Mamata fires back on Pahalgam and Delhi blast | 'A profound loss for Bangladesh politics': Sheikh Hasina mourns Khaleda Zia’s death | PM Modi mourns Khaleda Zia’s death, hails her role in India-Bangladesh ties | Bangladesh’s first female Prime Minister Khaleda Zia passes away at 80 | India rejects Pakistan’s Christmas vandalism remarks, cites its ‘abysmal’ minority record | Minority under fire: Hindu houses torched in Bangladesh village | Supreme Court puts Aravalli redefinition on hold amid uproar, awaits new expert committee | Supreme Court strikes! Kuldeep Sengar’s bail in Unnao case suspended amid public outcry | From bitter split to big reunion! Pawars join hands again for high-stakes civic battle

Strides annonces that it commenced export of Favipiravir Antiviral Tablets developed by it

| @indiablooms | May 01, 2020, at 02:55 pm

Kolkata/IBNS: Strides Pharma Science Limited (Strides), a global pharmaceutical company, has announced that it has developed and commercialized Favipiravir Antiviral tablets.

The product is a generic version of Avigan® of Toyama Chemical, Japan, the company said in a release.

It said Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan.

In February 2020, post the outbreak of Novel Coronavirus(Covid-19), Favipiravir was studied in China and several other countries as an experimental treatment of Covid-19.

The drug has demonstrated positive outcomes,including a reduction in the duration of Covid-19 and improved lung conditions for the patients, according to the company.

Strides said it has developed Favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration and the product is currently being exported to GCC countries to treat patients under their treatment program for Covid-19.

Strides said it will also immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available in India.

Favipiravir tablets are being manufactured at Strides’ flagship facility in Bangalore, India.

Strides said it has also entered into a preferred arrangement with a leading Indian API manufacturer for the supplies of Favipiravir API.

The partner has already commercialized the Favipiravir API from its USFDA, KFDA, PMDA and WHO approved manufacturing facility and has capabilities to manufacture the Favipiravir API from its Key Starting Material (KSM) in-house, Strides said in its release.

Dr R Ananthanarayanan, CEO and Managing Director of Strides, said, “We are the first Indian company to develop and commercially launch Favipiravir tablets for the global markets. Favipiravir has already demonstrated positive outcomes in several studies on Covid-19 patients, and we are hopeful that the treatment regime with Favipiravir would brace up our fight against this virus."

Strides is a leading Indian supplier of drugs in the anti-retroviral,  anti-malarial, hepatitis and other infectious disease drug segments.

Image Credit: Strides-Facebook

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm